Comprehensive Guide to Steroids in Clinical Practice

Critical Definitions and Risk Thresholds

Corticosteroids pose risk for adrenal insufficiency when BOTH criteria are met: therapy exceeding 3-4 weeks duration AND doses greater than physiologic equivalents (>15-25 mg hydrocortisone, >4-6 mg prednisone, >3-5 mg methylprednisolone, or >0.25-0.5 mg dexamethasone daily) 1.

Mortality risk increases significantly with chronic corticosteroid use, with an adjusted hazard ratio of 1.97 for all-cause mortality in rheumatoid arthritis patients, particularly with daily doses ≥5 mg prednisone equivalent 1.

Corticosteroid Tapering: A Structured Approach

Short-Term Therapy (<3-4 weeks)

Stop corticosteroids abruptly without tapering or testing, regardless of dose 1. HPA axis suppression is clinically irrelevant at this duration, though remain vigilant for other complications (sepsis, GI bleeding, thromboembolism, fractures) 1.

Long-Term Therapy (≥3-4 weeks at supraphysiologic doses)

Only attempt tapering when the underlying disease is controlled and no longer requires corticosteroid therapy 1.

Phase 1: Supraphysiologic Range Taper

Taper rapidly with large decrements when daily dose exceeds 30 mg prednisone equivalent
Reduce to approximately 7.5 mg prednisone (slightly above physiologic range)
Do NOT test for adrenal insufficiency during this phase—HPA suppression is expected 1
Monitor for glucocorticoid withdrawal syndrome (fatigue, myalgias, arthralgias occurring despite supraphysiologic dosing)
- If severe: temporarily increase to previous tolerated dose, then slow the taper 1

Phase 2: Physiologic Range Taper (4-6 mg prednisone)

Switch long-acting agents (dexamethasone, betamethasone) to short-acting agents (hydrocortisone, prednisone) before proceeding 1.

Choose one of two evidence-based approaches 1:

Option A - Clinical Monitoring Approach:

Gradually taper in small decrements while monitoring for adrenal insufficiency symptoms
If symptoms develop: restart glucocorticoid, do not discontinue until HPA recovery documented
If asymptomatic: continue tapering to discontinuation

Option B - Biochemical Testing Approach:

Measure morning serum cortisol (8:00-9:00 AM, 24 hours after last dose) 1
Interpretation as a continuum:
- >300 nmol/L (>10 μg/dL): HPA axis recovered, stop glucocorticoids safely
- 150-300 nmol/L (5-10 μg/dL): Continue physiologic dose, retest in weeks to months
- <150 nmol/L (<5 μg/dL): Continue physiologic dose, retest after several months
Do NOT routinely perform dynamic testing (ACTH stimulation) 1

Special Populations and Situations

Non-Oral Formulations

Maintain high suspicion for adrenal insufficiency in patients using 1:

High-dose inhaled corticosteroids (especially >1 year duration)
Topical corticosteroids (high-dose or >1 year)
Intra-articular injections (within previous 2 months)
Multiple simultaneous formulations
Concurrent strong CYP3A4 inhibitors (increases systemic exposure)

Patients with Cushing Syndrome Features

Assume glucocorticoid-induced adrenal insufficiency is present—do not attempt discontinuation without appropriate management 1.

Prolonged HPA Suppression

If HPA axis has not recovered after 1 year on physiologic replacement doses, refer to endocrinology for specialized evaluation 1.

Patient Education Requirements

All patients on corticosteroids must receive education about 1:

Risk of adrenal insufficiency and recognition of symptoms
Stress dosing requirements during illness, surgery, or trauma
Importance of gradual tapering
Distinction between withdrawal syndrome and true adrenal insufficiency
When to seek emergency care

Patients do NOT routinely require endocrinology referral unless complications arise or HPA recovery is delayed 1.

Anabolic-Androgenic Steroids (AAS)

Clinical Indications

Legitimate medical use is limited to specific hypogonadal states and rare conditions. The 2001 AACE guidelines describe use in hyperandrogenic disorders at physiologic replacement doses only 2.

Adverse Effects Profile

Cardiovascular complications are severe and dose-dependent 3, 4, 5:

Increased systolic BP by 12.43 mmHg and diastolic BP by 8.09 mmHg (pooled data)
Elevated thrombotic risk (both venous and arterial)
Mechanisms: polycythemia, platelet hyperaggregability, endothelial injury
Increased atherosclerosis risk via inflammatory pathways

Hepatotoxicity 6, 4:

AST elevation by 14.47 U/L, ALT elevation by 12.16 U/L (pooled data)
Risk of severe hepatic injury with certain agents

Endocrine disruption 6, 7, 4:

Profound testosterone suppression (mean decrease 141.57 ng/dL)
Post-use hypogonadism often prolonged or permanent
Hypothalamic-pituitary-gonadal axis dysfunction drives continued use (addiction mechanism)

Metabolic syndrome features 5:

Dyslipidemia: LDL-C increase by 9.12 mg/dL, HDL-C decrease
Impaired glucose metabolism
Hypertension

Additional complications 6, 8:

Acne vulgaris, gynecomastia, erectile dysfunction
Cardiomyopathy
Psychiatric effects and addiction potential 7

Management of AAS Users

Screening and monitoring requirements 8:

Most users (72%) fear reproach and avoid disclosing use
55% avoid seeking medical advice entirely
Establish non-judgmental communication to facilitate disclosure

Laboratory monitoring (though specific protocols lack consensus) 8:

Lipid panel, liver enzymes, complete blood count
Testosterone levels, gonadotropins
Blood pressure monitoring
Cardiovascular risk assessment

Multidisciplinary approach required 7:

Psychiatry/addiction medicine for use disorder and body dysmorphia
Endocrinology for hypogonadism management
Primary care for harm reduction strategies

Thrombotic Event Management

When thrombosis occurs 3:

Use standard anticoagulation regimens
Prefer low-molecular-weight heparin or direct oral anticoagulants over warfarin (avoid drug interactions)
Re-evaluate ongoing steroid necessity
Close bleeding risk monitoring

Critical Pitfalls to Avoid

Never test for adrenal insufficiency while on supraphysiologic doses—results are meaningless 1
Never abruptly stop long-term corticosteroids without appropriate tapering or HPA assessment
Do not dismiss AAS-related complications due to patient reluctance to disclose use 8
Do not use dexamethasone long-term when shorter-acting agents are appropriate 1
Do not confuse glucocorticoid withdrawal syndrome with adrenal insufficiency—the former occurs at supraphysiologic doses 1

What are the indications, dosing regimens, side effects, contraindications, monitoring requirements, and tapering guidelines for corticosteroids and anabolic‑androgenic steroids?

Have a follow-up question?